Protagonist Therapeutics Reports First Quarter Financial Results and Provides Corporate Update; -- Company selects the polycythemia vera indication for pivotal development of PTG-300 based on robust clinical responses --

Press/Media

Period7 May 2020 → 8 May 2020

Media coverage

20

Media coverage